Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;36(5):1088-1092.
doi: 10.1007/s12250-021-00411-w. Epub 2021 Jul 1.

Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study

Affiliations

Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study

Li Zhao et al. Virol Sin. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Detection of viral RNA and antibodies in samples of COVID-19 patients. A Comparison of viral RNA loads in COVID-19 patients detected by nasopharyngeal swab, sputum, and faecal samples (left) Viral RNA loads in COVID-19 patients with different clinical manifestations. B Serum IgM and IgG profiles in COVID-19 patients as analysed using RBD-based enzyme-linked immunosorbent assay (ELISA). a–c Cross-sectional profiles of absorbance at 450 nm (OD450nm) by IgM (a) and IgG (b) against RBD and by neutralising antibody (NAb) in a pseudovirus particle neutralisation test (c). Each dot represents an individual serum sample. d, Comparison of IgM, IgG, and NAb. e, Chronological changes (weeks after symptom onset) in IgM and IgG titres based on RBD-ELISA, and in NAb titres. f and g Changes in IgM (f) and IgG (g) levels between matched pairs of serum samples from COVID-19 patients. Each line represents an individual patient. C Detection of viral RNA and antibodies in SARS-CoV-2-infected patients. Results of matched-pair analysis to detect RNA (left) and antibody levels (right) in SARS-CoV-2-infected individuals. Classification: 1 indicated as asymptomatic patients, 2 indicated as mild patients, 3 indicated as moderate patients, 4 indicated as severe patients. *P < 0.05, **P < 0.01, ***P < 0.001.

Similar articles

References

    1. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow DS, Davey RT, Cohen JI. Detection of nucleocapsid antibody to SARS-CoV-2 is more sensitive than antibody to Spike protein in COVID-19 patients. China CDC Weekly. 2020;9:469.
    1. Chinese Center for Disease Control and Prevention Technical guidelines for COVID-19 laboratory testing. China CDC Weekly. 2020 doi: 10.46234/ccdcw2020.085. - DOI - PMC - PubMed
    1. Demey B, Daher N, François C, Lanoix JP, Duverlie G, Castelain S, Brochot E. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. J Infect. 2020;S0163:30244–30249. - PMC - PubMed
    1. Garbati MA, Fagbo SF, Fang VJ, Skakni L, Joseph M, Wani TA, Cowling BJ, Peiris M, Hakawi A. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS ONE. 2016;11:1–12. doi: 10.1371/journal.pone.0165978. - DOI - PMC - PubMed
    1. Han H, Luo Q, Mo F, Long L, Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients. Lancet Infect Dis. 2020;3099:30174. - PMC - PubMed